Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today
Potential short squeeze plays gained steam in 2021, continued throughout 2022, and remain a focus of new traders looking for the next huge move.
High short interest and steep borrowing costs are among the common traits that could lead to a short squeeze.
Potential short squeeze plays gained steam in 2021, continued through 2022, and remain a focus of new traders looking for the next huge move.
High-short interest and high-cost to borrow are among the common traits that could lead to a short squeeze.
Potential short squeeze plays gained steam in 2021, continued through 2022, and remain a focus of new traders looking for the next huge move.
High short interest and high cost to borrow are among the common traits that could lead to a short squeeze.
Potential shorts squeeze plays gained steam in 2021, continued through 2022, and remain a focus of new traders looking for the next huge move.
High short interest and high cost to borrow are among the common traits that could lead to a short squeeze.
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today
Potential short squeeze plays gained steam in 2021, continued through 2022, and remain a focus of new traders looking for the next huge move.
High short interest and high cost to borrow are among the common traits that could lead to a short squeeze.